New investment in Portal Biotech
We’re thrilled to back Portal Biotech in their $35M Series A, joining a standout syndicate alongside the NATO Innovation Fund (NIF), Earlybird Venture Capital, Science Creates, Pillar VC, 8VC and the British Business Bank.
Portal is pioneering the translation of a category-defining nanopore sequencing technology into the proteomics space. Their platform unlocks the world’s first full-length single-molecule protein sequencing – a long-standing “holy grail” in proteomics, with potential to reshape how we diagnose disease, develop drugs, and defend against biological threats.
Proteins drive biology. Portal’s AI-powered approach enables rapid, full-length protein characterisation on benchtop instruments – bringing deep molecular insights out of specialised labs and into everyday workflows.
Led by a team with deep expertise in nanopore biosensing and protein science, Portal is poised to lead a new era in life sciences – just as next-gen sequencing revolutionised genomics.
We’re proud to support this ambitious team as they reimagine what’s possible in proteomics.
“Portal is building a category-defining platform at the intersection of nanopore biosensing, AI, and proteomics -unlocking single-molecule, full-length protein sequencing for the first time. This breakthrough has the potential to fundamentally reshape diagnostics and drug development. At We VC, we’re proud to back visionary teams tackling foundational problems in science and engineering, and we believe Portal is set to lead a new era in molecular biology.”
Louise Warme, Head of We Venture Capital
For more information, please visit: